United States - English - NLM (National Library of Medicine)

remedyrepack inc. - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [ see clinical studies ( 14.2, 14.3) ]. letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [ see clinical studies ( 14.4, 14.5) ]. - pregnancy: letrozole can cause fetal harm [ see use in specific populations ( 8.1) ]. pr

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - letrozole - oral tablet - 2.5mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - letrozole 2,5 mg - film-coated tablet - 2,5 mg - letrozole 2.5 mg - letrozole

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - letrozole 2,5 mg - film-coated tablet - 2,5 mg - letrozole 2.5 mg - letrozole

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - letrozole 2,5 mg - film-coated tablet - 2,5 mg - letrozole 2.5 mg - letrozole

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see clinical studies (14.2, 14.3)] . letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see clinical studies (14.4, 14.5)]. - pregnancy: letrozole can cause fetal harm [see use in specific populations (8.1)] . - known hyp

United States - English - NLM (National Library of Medicine)

proficient rx lp - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see clinical studies (14.2, 14.3) ]. letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see clinical studies (14.4, 14.5) ]. risk summary based on postmarketing reports, findings from animal studies and the mechanism of act

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - estriol 0.5mg - pessary - 0.5 mg - active: estriol 0.5mg excipient: hard fat - atrophy of the lower urogenital tract related to oestrogen deficiency, notably · for the treatment of vaginal complaints such as dyspareunia, dryness and itching. · for the prevention of recurrent infections of the vagina and lower urinary tract. · in the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence.

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets, usp are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets, usp are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see clinical studies ( 14.2 , 14.3 ) ]. letrozole tablets, usp are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.letrozole tablets, usp are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression fol

Israel - English - Ministry of Health

novartis israel ltd - letrozole - film coated tablets - letrozole 2.5 mg - letrozole - letrozole - femara (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.